The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

Semaglutide, found in Ozempic and Wegovy, may lower dementia risk in diabetics, with stronger effects in older adults and women. The findings are based on data from nearly 1.7 million people.

American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss medication, Wegovy - may lower the risk of dementia in people with type 2 diabetes ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

Key Takeaways. Semaglutide significantly reduces ADRD risk compared to insulin, metformin, and older GLP-1RAs in type 2 diabetes patients. The study used a target trial emulation approach with ...

Ozempic and Mounjaro may also lower your risk of obesity-linked cancer. A study found another potential benefit of the weight loss drugs: lowered risk of chronic conditions.

Diabetes drug semaglutide linked to reduced risk of dementia in type 2 diabetes ... loss drug sold under brand names like Ozempic and Wegovy—may significantly lower the risk of ...